Business Context and Reporting Period
This Form 8-K is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on November 14, 2024. The report discloses the Company's financial results for the third quarter ended September 30, 2024, referencing a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It serves solely as a notification that third-quarter results have been issued.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The report includes standard disclaimers that forward-looking statements involve substantial risks and uncertainties. Terms such as "anticipates," "expects," and "believes" identify these statements.
- Risks: Actual results may differ materially from expressed expectations due to known and unknown risks, including those detailed in other SEC filings.
- Regulation FD: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Tivic Health Systems, Inc. (Ticker: TIVC), as the input metadata incorrectly listed "Valion Bio, Inc."
- Retrieve and review Exhibit 99.1 (Press Release dated November 14, 2024) to obtain actual financial figures for the quarter ended September 30, 2024.
- Confirm the Company's status as an Emerging Growth Company as indicated in the filing.
- Review the full list of risk factors in the Company's most recent 10-K or 10-Q to understand the specific uncertainties affecting forward-looking statements.